Trial Outcomes & Findings for Pelvic Alignment Level (PAL) Instrument Evaluation (NCT NCT01312428)

NCT ID: NCT01312428

Last Updated: 2017-11-17

Results Overview

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

7 participants

Primary outcome timeframe

6 week follow-up

Results posted on

2017-11-17

Participant Flow

Participant milestones

Participant milestones
Measure
PAL (Pelvic Alignment Level)
The cases randomized into the "PAL Group" will have total hip replacement surgery performed utilizing the PAL instrument. Pelvic Alignment Level (PAL) Instrument: Total hip replacement surgery will be performed utilizing the PAL Instrument.
No PAL (No Pelvic Alignment Level)
The cases randomized into the "No PAL Group" will have total hip replacement surgery performed without the use of the PAL instrument. This group will serve as the control group. Total Hip Replacement: Total hip replacement surgery will be performed without utilizing the PAL Instrument.
Overall Study
STARTED
3
4
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
3
4

Reasons for withdrawal

Reasons for withdrawal
Measure
PAL (Pelvic Alignment Level)
The cases randomized into the "PAL Group" will have total hip replacement surgery performed utilizing the PAL instrument. Pelvic Alignment Level (PAL) Instrument: Total hip replacement surgery will be performed utilizing the PAL Instrument.
No PAL (No Pelvic Alignment Level)
The cases randomized into the "No PAL Group" will have total hip replacement surgery performed without the use of the PAL instrument. This group will serve as the control group. Total Hip Replacement: Total hip replacement surgery will be performed without utilizing the PAL Instrument.
Overall Study
Study Termination
3
4

Baseline Characteristics

Pelvic Alignment Level (PAL) Instrument Evaluation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
PAL (Pelvic Alignment Level)
n=3 Participants
The cases randomized into the PAL group will have total hip replacement surgery performed utilizing the PAL instrument. Pelvic Alignment Level (PAL) Instrument: Total hip replacement surgery will be performed utilizing the PAL Instrument.
No PAL (No Pelvic Alignment Level)
n=4 Participants
The cases randomized into the no PAL group will have total hip replacement surgery performed without the use of the PAL instrument. This group will serve as the control group. Total Hip Replacement: Total hip replacement surgery will be performed without utilizing the PAL Instrument.
Total
n=7 Participants
Total of all reporting groups
Age, Continuous
65 years
STANDARD_DEVIATION 12.9 • n=39 Participants
65.9 years
STANDARD_DEVIATION 4.1 • n=41 Participants
65.5 years
STANDARD_DEVIATION 8.0 • n=35 Participants
Sex: Female, Male
Female
2 Participants
n=39 Participants
1 Participants
n=41 Participants
3 Participants
n=35 Participants
Sex: Female, Male
Male
1 Participants
n=39 Participants
3 Participants
n=41 Participants
4 Participants
n=35 Participants

PRIMARY outcome

Timeframe: 6 week follow-up

Population: The study was terminated early, therefore, primary or secondary measures were not assessed.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 week follow-up

Population: The study was terminated early, therefore, primary or secondary measures were not assessed.

Outcome measures

Outcome data not reported

Adverse Events

PAL (Pelvic Alignment Level)

Serious events: 1 serious events
Other events: 0 other events
Deaths: 0 deaths

No PAL (No Pelvic Alignment Level)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
PAL (Pelvic Alignment Level)
n=3 participants at risk
The cases randomized into the PAL group will have total hip replacement surgery performed utilizing the PAL instrument. Pelvic Alignment Level (PAL) Instrument: Total hip replacement surgery will be performed utilizing the PAL Instrument.
No PAL (No Pelvic Alignment Level)
n=4 participants at risk
The cases randomized into the no PAL group will have total hip replacement surgery performed without the use of the PAL instrument. This group will serve as the control group. Total Hip Replacement: Total hip replacement surgery will be performed without utilizing the PAL Instrument.
Injury, poisoning and procedural complications
Operative Site
33.3%
1/3 • Number of events 2 • 6 weeks
Industry Standard Adverse Event (AE) terms (e.g. MedDRA) were not used for AE data collection. Specific AE terms were not used for all AEs collected.
0.00%
0/4 • 6 weeks
Industry Standard Adverse Event (AE) terms (e.g. MedDRA) were not used for AE data collection. Specific AE terms were not used for all AEs collected.

Other adverse events

Adverse event data not reported

Additional Information

Director of Clinical Research

Stryker Orthopedics

Phone: 201-831-5401

Results disclosure agreements

  • Principal investigator is a sponsor employee To publish, exhibit or lecture, the manuscript, exhibit or speech must be provided to Stryker at least 60 days prior to submission for publication or presentation. The Investigator must receive consent from Stryker prior to publication, exhibition, or disclosure of scientific and clinical data. This review by Stryker is not intended to curtail distribution of scientific and clinical data, but to identify and edit any company confidential material and/or violations of FDA and FTC regulations.
  • Publication restrictions are in place

Restriction type: OTHER